Hongbo Hu's Lab
The State Key Laboratory of Biotherapy Si-Chuan University
γδ T cell for tumor immunothearpy

γδ T cells havebeen considered as a novel target for tumor immunotherapy, since they haveseveral very unique characters. However, the percentage of γδ T cell isvery low in the circulating blood so the research on this type of T cell is notsufficient. Here is a review about what is happening in this field.


γδ T cells form an important part ofadaptive immune responses against infections and malignant transformation. Themolecular targets of human γδ T cell receptors (TCRs)remain largely unknown, but recent studies have confirmed the recognition ofphosphorylated prenyl metabolites, lipids in complex with CD1 molecules andmarkers of cellular stress. All of these molecules are upregulated on variouscancer types, highlighting the potential importance of the γδT cell compartment in cancer immunosurveillance and paving the way for the useof γδ TCRs in cancer therapy. Ligand recognition by the γδ TCR often requires accessory/co-stimulatory stress moleculeson both T cells and target cells; this cellular stresscontext therefore provides a failsafe against harmful self-reactivity. Unlike αβ T cells, γδ T cells recognise theirtargets irrespective of HLA haplotype and therefore offer excitingpossibilities for off-the-shelf, pan-population cancer immunotherapies. Here,we present a review of known ligands of human γδ T cellsand discuss the promise of harnessing these cells for cancer treatment.

Read the review @http://www.nature.com/cmi/journal/vaop/ncurrent/full/cmi201528a.html